Ravin Ratan, MD, MEd, MD Anderson, delves into how treatment paradigms and considerations differ between adult patients and pediatric patients who have soft tissue sarcomas. Ravin Ratan, MD, MEd, ...

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...

Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today ...

This article first appeared with Targeted Oncology™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Clear cell sarcoma is an uncommon and aggressive soft tissue tumour that most often arises in the tendons and aponeuroses of young adults. It is distinguished by its melanocytic features and, in many ...

Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

Please provide your email address to receive an email when new articles are posted on . AYAs with sarcoma often develop acute and chronic pain due to their disease and the treatments they receive.